Sumitomo Pharma Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Sumitomo Pharma Bundle
See the Bigger Picture
Curious about Sumitomo Pharma's strategic product portfolio? This glimpse into their BCG Matrix highlights key areas, but the full report unlocks the complete picture of Stars, Cash Cows, Dogs, and Question Marks. Purchase the full version for detailed quadrant placements and data-backed recommendations to guide your investment and product decisions.
Stars
ORGOVYX (Relugolix)
ORGOVYX, a crucial product for Sumitomo Pharma, is a significant growth engine, especially in the North American market. Its strong sales performance has been instrumental in the company’s return to operating profit in fiscal year 2024.
Sumitomo Pharma reported that ORGOVYX’s sales in the U.S. and Canada reached approximately ¥100 billion (around $670 million USD based on average FY2024 exchange rates) in FY2024, a substantial increase from the previous year. This growth is a primary driver for the company’s positive financial turnaround.
Looking ahead to fiscal year 2025, Sumitomo Pharma anticipates ORGOVYX will maintain its momentum as a key revenue contributor. The company projects continued sales expansion for ORGOVYX, expecting it to further bolster profitability and market position.
MYFEMBREE (Relugolix, Estradiol, and Norethindrone Acetate)
MYFEMBREE, a combination therapy for uterine fibroids and endometriosis, stands as a significant revenue driver for Sumitomo Pharma in North America. The company's recent acquisition of full ownership of Myovant, MYFEMBREE's developer, underscores its commitment to maximizing the product's potential. This strategic move positions MYFEMBREE as a key asset in Sumitomo Pharma's growth trajectory.
GEMTESA (Vibegron)
GEMTESA, also known as vibegron, is a key player in Sumitomo Pharma's portfolio, demonstrating robust sales growth in the United States. Its expansion is driven by its effectiveness in treating overactive bladder (OAB), and the recent approval for OAB in men with benign prostatic hyperplasia (BPH) significantly broadens its market reach.
This expanded indication is a critical factor in GEMTESA's projected contribution to Sumitomo Pharma's financial performance. For instance, Sumitomo Pharma reported that GEMTESA achieved net sales of ¥35.1 billion (approximately $235 million USD based on an average 2024 exchange rate) in the fiscal year ending March 2024, a substantial increase that underscores its role as a growth driver.
iPS Cell-Derived Therapy for Parkinson's Disease (CT1-DAP001/DSP-1083)
Sumitomo Pharma's iPS cell-derived therapy for Parkinson's Disease, known as CT1-DAP001 or DSP-1083, is a groundbreaking regenerative medicine candidate. This therapy is positioned as a potential Star in the BCG matrix due to its innovative nature and significant growth prospects in the regenerative medicine sector.
The company is prioritizing its development, with the goal of securing approval in Japan promptly. Sales are anticipated to commence in the upcoming fiscal year, marking a critical milestone for this investigational treatment.
This therapy is projected to be a substantial long-term revenue generator for Sumitomo Pharma. The company has ambitious targets, aiming for this product to achieve JPY100 billion in annual sales by the mid-2030s, underscoring its status as a high-potential asset.
- World-First Innovation: CT1-DAP001/DSP-1083 represents a pioneering approach in Parkinson's disease treatment using iPS cell-derived therapy.
- Strategic Focus: It is a cornerstone of Sumitomo Pharma's regenerative medicine pipeline, a segment identified for high growth.
- Near-Term Commercialization: Approval in Japan is targeted as soon as possible, with sales expected to begin in the next fiscal year.
- Significant Revenue Potential: The therapy is forecast to become a JPY100 billion business by the mid-2030s, indicating strong future profitability.
Oncology Pipeline (e.g., Enzomenib/DSP-5336)
Sumitomo Pharma is making significant strides in its oncology pipeline, exemplified by enzomenib (DSP-5336). This candidate is being developed for acute leukemia and has garnered attention for its potential. The company's commitment to this area reflects a strategy to address critical unmet medical needs within oncology.
Enzomenib has achieved FDA Fast Track designation, a significant regulatory milestone that can accelerate the development and review process. Clinical data from Phase 1/2 studies have demonstrated encouraging efficacy in patients with relapsed or refractory acute myeloid leukemia. These results suggest a strong potential for enzomenib to become a valuable treatment option.
- Enzomenib (DSP-5336): A key oncology asset targeting acute leukemia.
- FDA Fast Track Designation: Granted for enzomenib, signaling its potential to address serious conditions.
- Clinical Efficacy: Phase 1/2 studies show promising results in relapsed/refractory AML.
- Market Positioning: Targets high-unmet-need areas, indicating strong growth potential upon successful development.
Sumitomo Pharma's Stars: Parkinson's & Leukemia Therapies
Sumitomo Pharma's iPS cell-derived therapy for Parkinson's Disease (CT1-DAP001/DSP-1083) is a prime example of a Star in the BCG matrix. This therapy is at the forefront of regenerative medicine, a sector with substantial growth potential. The company is actively pursuing its development, aiming for swift approval in Japan and anticipating sales to commence in the next fiscal year.
The projected revenue for this innovative treatment is significant, with Sumitomo Pharma targeting ¥100 billion in annual sales by the mid-2030s. This ambitious goal highlights the therapy's status as a high-potential asset poised for considerable future profitability and market expansion.
Enzomenib (DSP-5336), Sumitomo Pharma's oncology candidate for acute leukemia, also fits the profile of a Star. It has received FDA Fast Track designation, accelerating its development. Promising clinical data from Phase 1/2 studies in relapsed or refractory acute myeloid leukemia underscore its potential to become a key revenue driver in a high-unmet-need area.
| Product | Therapeutic Area | BCG Category | Key Developments/Data (as of July 2025) | Projected Impact |
| CT1-DAP001/DSP-1083 | Parkinson's Disease (Regenerative Medicine) | Star | World-first iPS cell-derived therapy. Japan approval targeted soon, sales expected next fiscal year. Projected ¥100 billion annual sales by mid-2030s. | Significant long-term revenue generator, high growth potential. |
| Enzomenib (DSP-5336) | Acute Leukemia (Oncology) | Star | FDA Fast Track designation. Promising Phase 1/2 data in relapsed/refractory AML. | Potential to address high unmet need, strong growth upon successful development. |
What is included in the product
Detailed Word Document
This Sumitomo Pharma BCG Matrix overview highlights which business units to invest in, hold, or divest based on market growth and share.
Customizable Excel Spreadsheet
The Sumitomo Pharma BCG Matrix provides a clear, one-page overview of each business unit's strategic position, relieving the pain of complex portfolio analysis.
Cash Cows
North American Key Product Portfolio
Sumitomo Pharma's North American key product portfolio, comprising ORGOVYX, MYFEMBREE, and GEMTESA, is currently the company's primary revenue driver. These products are crucial for generating consistent revenue increases, supporting the company's ongoing restructuring and investments in new growth opportunities.
The robust performance of these products has been instrumental in Sumitomo Pharma achieving an operating profit. For instance, ORGOVYX alone reported net sales of ¥100.5 billion in the fiscal year ending March 2024, demonstrating its significant contribution to the company's financial turnaround.
MEROPEN (in China)
MEROPEN, a key antibiotic, is a strong performer within Sumitomo Pharma's portfolio, particularly in the dynamic Asian market. Its significant contribution to sales in China highlights a well-established product with a robust market presence.
This steady revenue generation, characteristic of a cash cow, provides Sumitomo Pharma with reliable financial backing. While MEROPEN may not be in a high-growth phase, its consistent performance ensures a stable income stream, crucial for funding other business initiatives.
TWYMEEG
TWYMEEG, a treatment for type 2 diabetes, has been a consistent performer in Japan, contributing significantly to Sumitomo Pharma's domestic revenue. Its steady sales growth highlights its established position in a mature market, acting as a crucial revenue stabilizer for the company.
RETHYMIC (Allogeneic Processed Thymus Tissue-agdc)
RETHYMIC, a regenerative therapy for pediatric congenital athymia, began sales in the U.S. in March 2022. This specialized treatment targets a specific medical need, positioning it as a potential cash cow for Sumitomo Pharma. Its commercialization as a regenerative medicine product suggests a steady revenue stream within its niche market.
As a commercialized product, RETHYMIC contributes consistently to Sumitomo Pharma's revenue. The therapy addresses a rare condition, congenital athymia, which means it operates in a specialized market. This focus allows for potentially stable demand and predictable sales, characteristic of a cash cow.
- Product: RETHYMIC (Allogeneic Processed Thymus Tissue-agdc)
- Indication: Pediatric congenital athymia
- U.S. Launch: March 2022
- Market Position: Niche, regenerative medicine
Operational Efficiency and Cost Reductions
Sumitomo Pharma's focus on operational efficiency and cost reductions acts as a crucial cash cow, bolstering its financial stability. The company has actively pursued restructuring and implemented significant cost-cutting initiatives. These efforts have notably included reductions in Selling, General, and Administrative (SG&A) expenses and research and development (R&D) expenditures. For instance, in the fiscal year ending March 2024, Sumitomo Pharma reported a significant improvement in its financial performance, returning to profitability driven by these efficiency gains.
These strategic operational improvements, though not a product itself, function similarly to a cash cow by directly enhancing profit margins. By trimming unnecessary costs, more cash is generated and retained within the company. This increased cash flow is vital, providing the necessary capital to reinvest in promising growth areas and support future innovation. The company's commitment to optimizing its operations ensures a more robust financial foundation for sustained growth and market competitiveness.
- Reduced SG&A and R&D Expenses: Sumitomo Pharma has streamlined operations, leading to lower overhead costs and more targeted R&D investments.
- Return to Profitability: These efficiencies were a key driver in Sumitomo Pharma achieving profitability in its fiscal year ending March 2024.
- Enhanced Cash Flow: Improved profit margins free up capital, creating a reliable internal source of funding for strategic initiatives.
- Strategic Reinvestment: The generated cash supports investments in high-potential new drugs and therapeutic areas, fueling future growth.
Sumitomo Pharma's Revenue: Cash Cows and Strategic Efficiency
Sumitomo Pharma's established products like ORGOVYX and MEROPEN are performing strongly, generating consistent revenue that functions as cash cows. ORGOVYX, in particular, achieved net sales of ¥100.5 billion in the fiscal year ending March 2024, a testament to its significant contribution. MEROPEN also shows robust sales, especially in the Asian market, underscoring its role as a reliable income source.
TWYMEEG in Japan and RETHYMIC in the U.S. also contribute steadily to Sumitomo Pharma's revenue. TWYMEEG stabilizes domestic income, while RETHYMIC, a niche regenerative therapy launched in March 2022 for pediatric congenital athymia, provides predictable sales within its specialized market.
Beyond specific products, Sumitomo Pharma's focus on operational efficiency, including reductions in SG&A and R&D expenses, acts as a crucial internal cash cow. These cost-saving measures were instrumental in the company returning to profitability in the fiscal year ending March 2024, freeing up capital for strategic reinvestment.
| Product | Fiscal Year Ending March 2024 Net Sales (¥ billion) | Market | BCG Category |
| ORGOVYX | 100.5 | North America | Cash Cow |
| MEROPEN | N/A (Strong contributor) | Asia | Cash Cow |
| TWYMEEG | N/A (Consistent performer) | Japan | Cash Cow |
| RETHYMIC | N/A (Steady revenue) | U.S. (Niche) | Cash Cow |
What You See Is What You Get
Sumitomo Pharma BCG Matrix
The Sumitomo Pharma BCG Matrix preview you are viewing is the identical, fully formatted report you will receive immediately after purchase. This means you get access to the complete strategic analysis without any watermarks or demo content, ensuring you can directly apply it to your business planning. The document is meticulously prepared, offering a professional and actionable breakdown of Sumitomo Pharma's product portfolio based on market share and growth rate. You can confidently use this preview as a true representation of the valuable insights contained within the purchased file, ready for immediate integration into your strategic discussions.
Dogs
Latuda (Lurasidone)
Latuda (lurasidone) has definitively moved into the 'Dog' category for Sumitomo Pharma. Following the loss of U.S. market exclusivity in February 2023, its sales plummeted, directly impacting the company's financial performance.
This patent cliff resulted in a substantial revenue drop for Latuda, illustrating a classic case of a blockbuster drug becoming a 'Dog' due to the emergence of generic alternatives. Sumitomo Pharma reported a significant decline in their North America segment, largely attributable to this situation.
TRERIEF
TRERIEF, a product within Sumitomo Pharma's portfolio, has seen its Japanese sales decline significantly following the loss of market exclusivity. This loss has opened the door for generic competitors, directly impacting TRERIEF's market share and revenue streams.
The product's diminished competitive advantage suggests it may be a candidate for reduced investment or eventual divestiture. For instance, in the fiscal year ending March 2024, Sumitomo Pharma reported a substantial decrease in revenue from its established products in Japan, a trend that TRERIEF's situation exemplifies.
Equa®
Equa®, a therapeutic agent for type 2 diabetes, experienced a significant downturn after losing its exclusivity period in December 2024. This event directly led to a substantial decrease in its sales figures, reflecting the immediate impact of generic competition entering the market.
The loss of exclusivity for Equa® mirrors the challenges faced by TRERIEF, making it increasingly difficult for the drug to hold onto its market share and profitability. The availability of more affordable generic versions presents a formidable challenge to maintaining its competitive edge and revenue streams.
Consequently, Equa® has transitioned into a low-growth, low-market-share segment of the BCG matrix. This classification indicates that the product is no longer a significant growth driver for Sumitomo Pharma and faces limited opportunities for expansion in its current market environment.
APTIOM (Eslicarbazepine Acetate)
APTIOM, an antiepileptic drug, experienced a revenue decline in Q1 FY2025. This downturn is directly attributable to the loss of market exclusivity, which opened the door for generic competitors.
While there were some price increases in the preceding fiscal year that temporarily boosted revenue, the impact of generic entry has proven more significant. This erosion of market share and profitability positions APTIOM as a product likely requiring substantial investment for minimal return in a shrinking market.
- APTIOM Revenue Decline: Experienced a decrease in Q1 FY2025 due to loss of exclusivity.
- Generic Competition Impact: Generic entry has diminished market share and profitability.
- Resource Allocation: APTIOM now likely demands more resources than it generates in a declining market.
Non-core or Underperforming Assets/Businesses
Sumitomo Pharma has actively streamlined its portfolio, a key move involving the divestment of its entire stake in Roivant Sciences Ltd. This strategic maneuver, alongside other asset sales, signals a clear intent to shed non-core or underperforming business units.
These divestments are not isolated incidents but part of a broader business structural reform. By exiting or reducing investment in areas not meeting return expectations, Sumitomo Pharma aims to enhance overall financial performance and focus resources on more promising ventures.
The company's actions, including employee reductions and restructuring in North America, further underscore this commitment to optimizing its business structure. For instance, the sale of its Roivant stake in late 2023 was a significant step, impacting its investment portfolio and operational focus.
- Divestment of Roivant Sciences Ltd. stake: Sumitomo Pharma completed the sale of its entire stake in Roivant Sciences Ltd., a significant move to exit a non-core investment.
- Focus on core competencies: This action is part of a wider strategy to offload underperforming assets and concentrate on businesses with higher return potential.
- North American restructuring: Employee reductions and organizational changes in North America further support the goal of improving efficiency and profitability in key markets.
Patent Expiry Woes: Drugs Facing the 'Dog' Days
Sumitomo Pharma's portfolio includes several products that have transitioned into the 'Dog' category of the BCG matrix. These are typically drugs that have lost market exclusivity, facing significant generic competition and experiencing declining sales and market share. Latuda, TRERIEF, Equa®, and APTIOM are prime examples, each illustrating the challenges of maintaining market position after patent expiry.
| Product | Status | Reason | Financial Impact |
| Latuda | Dog | Loss of U.S. market exclusivity (Feb 2023) | Significant sales plummet, impacting North America segment revenue. |
| TRERIEF | Dog | Loss of market exclusivity in Japan | Declining Japanese sales, reduced market share due to generic competition. |
| Equa® | Dog | Loss of exclusivity (Dec 2024) | Substantial decrease in sales figures following generic entry. |
| APTIOM | Dog | Loss of market exclusivity | Revenue decline in Q1 FY2025 due to generic competition. |
Question Marks
Oncology Pipeline: Nuvisertib (TP-3654)
Nuvisertib (TP-3654) represents Sumitomo Pharma's potential contender in the oncology pipeline, specifically targeting myelofibrosis. This investigational drug, a PIM1 kinase inhibitor, is currently navigating Phase 1/2 clinical trials. Its journey has been bolstered by an FDA Fast Track designation, signaling a recognized need for new treatments in this indication.
Myelofibrosis, while presenting a significant unmet medical need and offering growth potential, demands substantial research and development investment. Nuvisertib’s current stage means its ultimate clinical efficacy and commercial success are still to be fully determined, placing it in a position where it could potentially evolve into a 'Star' product for Sumitomo Pharma.
Regenerative Medicine: iPS Cell-Derived Retinal Pigment Epithelial Cells (HLCR011)
Sumitomo Pharma's HLCR011, a therapy using iPS cell-derived retinal pigment epithelial cells for retinal pigment epithelium tears, is currently in Phase 1/2 clinical trials in Japan. This positions it as a potential Question Mark within the BCG Matrix, given the nascent stage of development for this regenerative medicine product. Regenerative medicine itself is a burgeoning sector with significant projected growth, estimated to reach over $100 billion globally by 2030, but HLCR011's early-stage status means it requires considerable investment for clinical validation and market entry.
Regenerative Medicine: iPS Cell-Derived Retinal Sheet (DSP-3077)
The iPS cell-derived retinal sheet, DSP-3077, targets retinitis pigmentosa, a condition affecting millions globally. Currently in Phase 1/2 clinical trials in the U.S., this therapy represents a significant investment in the burgeoning regenerative medicine market. While its future market share is unproven, the substantial ongoing capital required for its development places it firmly in the question mark category of the BCG matrix.
Early-Stage Psychiatry & Neurology Pipeline
Sumitomo Pharma's early-stage psychiatry and neurology pipeline, including compounds like DSP-0038 for Alzheimer's disease psychosis, DSP-0187 for narcolepsy, and DSP-3456 for treatment-resistant depression, represents potential future growth drivers. These investigational drugs are currently in Phase 1 trials, indicating significant development risk and substantial investment needs.
These early-stage assets are categorized as Stars or Question Marks in the BCG matrix, depending on their perceived future market potential and current stage of development. While the therapeutic areas of psychiatry and neurology are experiencing growth, these specific compounds have minimal current market share, necessitating substantial R&D expenditure to advance through clinical phases and achieve commercialization.
- DSP-0038: Investigational treatment for Alzheimer's disease psychosis, currently in Phase 1 in the U.S.
- DSP-0187: Investigational treatment for narcolepsy, in Phase 1 trials in Japan.
- DSP-3456: Investigational treatment for treatment-resistant depression, undergoing Phase 1 studies in the U.S.
- Market Potential: These represent high-growth therapeutic areas with significant unmet medical needs, offering substantial future market opportunities if successful.
Other Early-Stage Oncology Pipeline
Sumitomo Pharma's early-stage oncology pipeline includes promising candidates beyond its more advanced programs. For instance, DSP-0390 is currently in Phase 1 trials in both the U.S. and Japan for glioblastoma, a particularly aggressive form of brain cancer.
Another asset, SMP-3124, is also in early development, with Phase 1/2 studies underway in the U.S. and Japan for various solid tumors. These compounds address significant unmet medical needs within oncology.
Given their current developmental stage and limited market presence, these assets would be categorized as question marks in a BCG matrix framework. This classification highlights their potential but also the substantial investment required to advance them through clinical trials and towards market approval.
- DSP-0390: Phase 1 for glioblastoma (U.S./Japan).
- SMP-3124: Phase 1/2 for solid tumors (U.S./Japan).
- Unmet Need: Both target serious diseases with high patient impact.
- BCG Classification: Question marks due to early stage and low market share.
Sumitomo Pharma's Pipeline: High Risk, High Reward
Sumitomo Pharma's HLCR011, a regenerative medicine product for retinal pigment epithelium tears, is in early-stage clinical trials. This positions it as a question mark due to its nascent development and significant investment needs. The broader regenerative medicine market is projected to exceed $100 billion globally by 2030, indicating substantial future potential for successful therapies.
DSP-3077, targeting retinitis pigmentosa, is also in Phase 1/2 trials in the U.S. This therapy requires considerable capital for development, placing it in the question mark category of the BCG matrix. The significant investment reflects the high risk and potential reward in this burgeoning sector.
Sumitomo Pharma's early-stage psychiatry and neurology pipeline, including treatments for Alzheimer's disease psychosis and narcolepsy, are all in Phase 1 trials. These represent high-growth therapeutic areas but require substantial R&D expenditure, classifying them as question marks with minimal current market share.
Early-stage oncology candidates like DSP-0390 for glioblastoma and SMP-3124 for solid tumors are in Phase 1/2 development. These address critical unmet needs but, due to their developmental stage, are classified as question marks, requiring significant investment to reach commercialization.
BCG Matrix Data Sources
Our Sumitomo Pharma BCG Matrix leverages comprehensive market data, including sales figures, R&D investments, and competitor analysis, to accurately position each business unit.
